6-K

UNITED STATES

SECURITIES ANDEXCHANGE COMMISSION

WASHINGTON, D.C.20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of March 2023

Commission File Number 001-37652

Midatech PharmaPLC

(Translation of registrant’s name intoEnglish)

1 Caspian Point,

Caspian Way,

Cardiff, CF10 4DQ, United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXPLANATORY NOTE

On March 10, 2023, Midatech Pharma PLC (the “Company”) issued a press release announcing the correction of certain typographical errors identified within the Company’s Circular and Notice of General Meeting (the “Circular”) previously posted to its shareholders with respect to a General Meeting to be held on March 24, 2023. A copy of the press release is furnished hereto as Exhibit 99.1.

The information in the attached Exhibit 99.1 is being furnishedand shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the“Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by referencein any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, exceptas otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

SUBMITTED HEREWITH

Attached to the Registrant’s Form 6-K filing for the month of March 2023 is:

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Exhibit 99.1

10 March 2023

Midatech Pharma PLC

(“Midatech” or the “Company”)

Further re: Notice of General Meeting- Correction of Typographical Errors

Further to the announcement made on 8 March 2023 providing notice of a general meeting (the “GM”) of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the “Notice”) and form of proxy (the “Form of Proxy”), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:

As such errors are administrative in nature, no new Notice will be published and the aforementioned amendments to Resolution 4 and Resolution 5 will be effected by a motion to be passed at the GM. Furthermore, no new Form of Proxy will be posted to shareholders but a copy of the corrected Form of Proxy will be made available on the Company's website at: www.midatechpharma.com/. Any shareholder who wishes to change any proxy instructions already submitted may do so by submitting a new proxy appointment using the method set out in the notes to the Notice.